This company has been acquired
Science 37 Holdings (SNCE) Stock Overview
Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
SNCE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Science 37 Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.75 |
| 52 Week High | US$12.96 |
| 52 Week Low | US$3.73 |
| Beta | 0.57 |
| 1 Month Change | 1.23% |
| 3 Month Change | 30.39% |
| 1 Year Change | 30.86% |
| 3 Year Change | -97.22% |
| 5 Year Change | n/a |
| Change since IPO | -97.14% |
Recent News & Updates
Recent updates
Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks
Dec 18
Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)
Apr 17Science 37, Syapse team for faster patient enrollment in cancer trials
Aug 18Science 37 reports Q2 mixed earnings; narrows FY22 guidance
Aug 11Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
May 13Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans
Apr 11Science 37: Pioneering Decentralized Clinical Trials
Jan 02We Think Science 37 Holdings (NASDAQ:SNCE) Can Afford To Drive Business Growth
Nov 04Shareholder Returns
| SNCE | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0.3% | 0.7% | -0.3% |
| 1Y | 30.9% | -5.7% | 13.9% |
Return vs Industry: SNCE exceeded the US Life Sciences industry which returned 9% over the past year.
Return vs Market: SNCE matched the US Market which returned 31% over the past year.
Price Volatility
| SNCE volatility | |
|---|---|
| SNCE Average Weekly Movement | 15.6% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SNCE's share price has been volatile over the past 3 months.
Volatility Over Time: SNCE's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 460 | Dave Coman | www.science37.com |
Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company’s platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area.
Science 37 Holdings, Inc. Fundamentals Summary
| SNCE fundamental statistics | |
|---|---|
| Market cap | US$34.67m |
| Earnings (TTM) | -US$124.65m |
| Revenue (TTM) | US$60.26m |
Is SNCE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNCE income statement (TTM) | |
|---|---|
| Revenue | US$60.26m |
| Cost of Revenue | US$38.14m |
| Gross Profit | US$22.12m |
| Other Expenses | US$146.77m |
| Earnings | -US$124.65m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -20.67 |
| Gross Margin | 36.71% |
| Net Profit Margin | -206.85% |
| Debt/Equity Ratio | 0% |
How did SNCE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/11 06:22 |
| End of Day Share Price | 2024/03/11 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Science 37 Holdings, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Coldwell | Baird |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Frank Takkinen | Lake Street Capital Markets, LLC |